

## **POSTER PRESENTATION**

**Open Access** 

PReS-FINAL-2063: Proposed criteria for activity, damage and impact of juvenile idiopathic arthritis associated uveitis: consensus effort from the multinational interdisciplinary working group for uveitis in childhood (MIWGUC)

I Foeldvari<sup>1\*</sup>, A Heiligenhaus<sup>2</sup>, J Anton<sup>3</sup>, R Ramanan<sup>4</sup>, C Edelsten<sup>5</sup>, T Saurenmann<sup>6</sup>, B Bodaghi<sup>7</sup>, K Kotaniemi<sup>8</sup>, S Nielsen<sup>9</sup>, E Rabinovich<sup>10</sup>, Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)

From 20th Pediatric Rheumatology European Society (PReS) Congress Ljubljana, Slovenia. 25-29 September 2013

#### Introduction

Uveitis is the most common extraartricular manifesation of juvenile idiopathic arthritis (JIA) with an incidence of approx. 10 - 15 per 100,000 children. Uveitis, a potentially blinding disorder, is present in approx 10-18% of JIA patients, with a wide spectrum of presentations. Despite advances in treatment of childhood arthritis there are no definitions for assessment of activity, damage and impact of JIA associated uveitis.

## **Objectives**

The purpose of our efforts was to develop and gain consensus on such definitions as activity and damage.

#### **Methods**

At the second consensus meeting of the MIWGUC group, using a Delphi method we developed definitions for activity, damage and impact of disease based on already published outcome measures [1].

#### Results

The following items were included and listed in Table 1. The items were derived from the previously proposed and already published list of outcome measures [1].

Following items were selected to present activity: anterior chamber cells, flare, vusual acuity, syncechiae,macular edema ocular hyptony, ocular hypertension, CHAQ, number of medication and local eyedrops. Folowing items were selected to present damaga:flare, visual acuity, synechiae,cataract, macular edema, ocular hypotony and hypertony, glaucoma, disc edema, band keratopahty, epiretinal membranes and overall uveiits disability VAS.

## Conclusion

We will validate these proposed definitions propsectively in a JIA associated uveitis cohort. Based on the results, we will weight these measures to develop an overall scoring system.

## **Disclosure of interest**

None declared.

## Authors' details

<sup>1</sup>Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany. <sup>2</sup>Ophthalmology, Müster, Germany. <sup>3</sup>Pediatric Rheumatology, Barcelona, Spain. <sup>4</sup>Pediatric Rheumatology, Bristol, UK. <sup>5</sup>Great Ormond Street Hospital, London, UK. <sup>6</sup>PediatricRheumatology, Zürich, Switzerland. <sup>7</sup>Ophthalmology, Paris, France. <sup>8</sup>Ophthalmologist, Helsinki, Finland. <sup>9</sup>Pediatric Rheumatology, Copenhagen, Denmark. <sup>10</sup>Pediatric Rheumatology, Durham, USA

Published: 5 December 2013

Full list of author information is available at the end of the article



 $<sup>\</sup>overline{\ \ }$  Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany

#### Reference

 Heiligenhaus A, et al: Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res (Hoboken) 2012, 64(9):1365-72.

#### doi:10.1186/1546-0096-11-S2-P75

Cite this article as: Foeldvari et al.: PReS-FINAL-2063: Proposed criteria for activity, damage and impact of juvenile idiopathic arthritis associated uveitis: consensus effort from the multinational interdisciplinary working group for uveitis in childhood (MIWGUC). Pediatric Rheumatology 2013 11(Suppl 2):P75.

# Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

